Clinical Trial Update: A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA <200IU/ml [NA]

View source ↗

Summary

This clinical trial update evaluates switching CHB patients who achieved HBeAg loss and HBV DNA <200 IU/mL from nucleotide therapy to Peginterferon alfa-2a.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Peginterferon alfa-2a (peginterferon alfa-2a)

Snippet

Sponsor: The Second Affiliated Hospital of Chongqing Medical University | Conditions: Chronic Hepatitis B | NA | Status: UNKNOWN